Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?

ABSTRACT: Pancreatic cancer remains one of the most lethal malignant diseases worldwide. The majority of patients present with advanced disease and, therefore, need palliative chemotherapy. Some chemotherapeutic regimens have been well established as first-line therapies and have been shown to increase survival; however, almost all patients with advanced pancreatic cancer will experience disease progression after first-line therapy. Nevertheless, many patients who retain good performance status after initial treatment remain good candidates for additional therapy. Historically, few studies have assessed second-line therapy, with most reports representing small phase II trials with variable findings; however, clinical research for second-line treatment has increased in the past decade, and several ra

SUBMITTER: Hua J 

PROVIDER: S-EPMC6084072 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature